In the US, Regorafenib (regorafenib systemic) is a member of the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Colorectal Cancer, Gastrointestinal Stromal Tumor and Hepatocellular Carcinoma.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
- Regorafenibum (Latin)
- Regorafenib (German)
- Régorafénib (French)
- Regorafenib (Spanish)
- Regorafenib (OS: USAN)
- BAY 73-4506 (IS)
- UNII-24T2A1DOYB (IS)
- Regorafenib Hydrate (OS: JAN)
Bayer Santé, France
Bayer, Bosnia & Herzegowina; Bayer, Canada; Bayer, Chile; Bayer, Denmark; Bayer, United Kingdom; Bayer, Greece; Bayer, Hong Kong; Bayer, Croatia (Hrvatska); Bayer, Hungary; Bayer, Ireland; Bayer, Iceland; Bayer, Italy; Bayer, Poland; Bayer, Romania; Bayer, Sweden; Bayer, Slovakia; Bayer HealthCare, Finland; Bayer Pharma, Austria; Bayer Pharma, Israel; Bayer Pharma, Slovenia; Bayer Pharma AG, Norway; Bayer Santé, France; Bayer Vital, Germany; Bayer, South Korea; Bayer HealthCare, Singapore; Bayer HealthCare, United States; Bayer Thai Co Ltd, Thailand; Bayer Yakuhin, Japan
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.